Rebamipide increases barrier function and attenuates TNFα-induced barrier disruption and cytokine expression in human corneal epithelial cells

British Journal of Ophthalmology

Volumn 97, Issue 7, 2013, Pages 912-916

  Tanaka, Hiroshi ^a   Fukuda, Ken ^b   Ishida, Waka ^b   Harada, Yosuke ^b   Sumi, Tamaki ^b   Fukushima, Atsuki ^b  

^a Machida Hospital   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROTEIN ZO1; REBAMIPIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORNEA CELL; CORNEAL EPITHELIAL BARRIER FUNCTION; CORNEAL EPITHELIAL CELL; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; ELECTRIC RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; VISUAL SYSTEM PARAMETERS;

DRUGS; EXPERIMENTAL 8211 LABORATORY; INFLAMMATION; OCULAR SURFACE; TEARS;

ALANINE; ANTIOXIDANTS; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; QUINOLONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84879417457     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302868     Document Type: Article

References (26)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92.
2. Boehm N, Riechardt AI, Wiegand M, et al. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011;52:7725-30.
3. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009;147:198-205 e1.
4. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11.
5. Kimura K, Teranishi S, Fukuda K, et al. Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-α in a manner dependent on NF-κB. Invest Ophthalmol Vis Sci 2008;49:565-71.
6. Fahim MM, Haji S, Koonapareddy CV, et al. Fluorophotometry as a diagnostic tool for the evaluation of dry eye disease. BMC Ophthalmol 2006;6:20.
7. Naito Y, Yoshikawa T, Iinuma S, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 1998;43:83-9S.
8. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010;4:261-70.
9. Takeji Y, Urashima H, Aoki A, et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther 2012;28:259-63.
10. Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004;23:613-19.
11. Urashima H, Takeji Y, Okamoto T, et al. Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits. J Ocul Pharmacol Ther 2012;28:264-70.
12. Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;119:2471-8.
13. Kashima T, Akiyama H, Miura F, et al. Resolution of persistent corneal erosion after administration of topical rebamipide. Clin Ophthalmol 2012;6:1403-6.
14. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28:1023-7.
15. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 1995;36:614-21.
16. Fukuda K, Kumagai N, Yamamoto K, et al. Potentiation of lipopolysaccharide-induced chemokine and adhesion molecule expression in corneal fibroblasts by soluble CD14 or LPS-binding protein. Invest Ophthalmol Vis Sci 2005;46:3095-101.
17. Ritchie MH, Fillmore RA, Lausch RN, et al. A role for NF-κB binding motifs in the differential induction of chemokine gene expression in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004;45:2299-305.
18. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42.
19. Gipson IK, Hori Y, Arqueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004;2:131-48.
20. Argueso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci 2002;43:1004-11.
21. Danjo Y, Watanabe H, Tisdale AS, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998;39:2602-9.
22. Rios JD, Shatos M, Urashima H, et al. OPC-12759 increases proliferation of cultured rat conjunctival goblet cells. Cornea 2006;25:573-81.
23. Blalock TD, Spurr-Michaud SJ, Tisdale AS, et al. Release of membrane-associated mucins from ocular surface epithelia. Invest Ophthalmol Vis Sci 2008;49:1864-71.
24. Lee KH, Kim JY, Kim WK, et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci 2011;56:441-8.
25. Matysiak-Budnik T, Thomas-Collignon A, Megraud F, et al. Alterations of epithelial permeability by Helicobacter and IL-1β in vitro: protective effect of rebamipide. Dig Dis Sci 2001;46:1558-66.
26. Choe JY, Park KY, Lee SJ, et al. Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells. Inflamm Res 2010;59:1019-26.